Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Recovery 1% Improvement Relative Risk Viral clearance 3% Symptomatic rebound -171% Viral rebound -52% c19early.org/pl Pandit et al. Paxlovid for COVID-19 EARLY TREATMENT Favors paxlovid Favors control
The Paxlovid Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences Between Paxlovid and Untreated COVID-19 Participants
Pandit et al., medRxiv, doi:10.1101/2022.11.14.22282195 (Preprint)
15 Nov 2022    Source   PDF   Share   Tweet
Prospective study of 170 COVID-19 patients in the USA, showing no significant difference in symptomatic and viral recovery times, and higher risk of symptomatic rebound, without statistical significance. There were more elderly patients in the paxlovid group.
5 paxlovid patients did not test negative during the 16 day daily followup, compared to zero for control. Only patients testing negative or reporting no symptoms were included in the recovery time analyses. KM curves show no significant difference in viral or symptomatic recovery.
risk of no recovery, 1.2% lower, RR 0.99, p = 0.90.
risk of no viral clearance, 2.9% lower, RR 0.97, p = 0.73.
symptomatic rebound, 170.9% higher, RR 2.71, p = 0.06, treatment 24 of 127 (18.9%), control 3 of 43 (7.0%).
viral rebound, 52.4% higher, RR 1.52, p = 0.41, treatment 18 of 127 (14.2%), control 4 of 43 (9.3%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pandit et al., 15 Nov 2022, prospective, USA, preprint, 8 authors, study period 4 August, 2022 - 1 November, 2022.
Contact: jpandit@scripps.edu.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperPaxlovidAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit